These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1672895)

  • 1. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy.
    Hartley R; Aleksandrowicz J; Bowmer CJ; Cawood A; Forsythe WI
    J Pharm Pharmacol; 1991 Feb; 43(2):117-9. PubMed ID: 1672895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients.
    Silpakit O; Amornpichetkoon M; Kaojarern S
    Ann Pharmacother; 1997 May; 31(5):548-52. PubMed ID: 9161646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability?
    Hartley R; Aleksandrowicz J; Ng PC; McLain B; Bowmer CJ; Forsythe WI
    Br J Clin Pract; 1990 Jul; 44(7):270-3. PubMed ID: 2206824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.
    Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM
    Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
    Patsalos PN
    Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market.
    Oluka MO; Mitema ES; Kibwage IO; Kwasa TO; Kokwaro GO
    East Afr Med J; 1996 May; 73(5):323-6. PubMed ID: 8756037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients.
    Morselli PL; Monaco F; Gerna M; Recchia M; Riccio A
    Epilepsia; 1975 Dec; 16(5):759-64. PubMed ID: 1222752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the biological availability of 2 carbamazepine preparations].
    Niedzielska K; Rosnowska M; Kuran W
    Neurol Neurochir Pol; 1986; 20(5):415-20. PubMed ID: 3295573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of absorption rate and bioavailability of two brands of carbamazepine.
    Revankar SN; Desai ND; Bhatt AD; Bolar HV; Sane SP; Gupta C; Kamat DV
    J Assoc Physicians India; 1999 Jul; 47(7):699-702. PubMed ID: 10778590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic bioequivalency study of brand name versus generic carbamazepine.
    Oles KS; Penry JK; Smith LD; Anderson RL; Dean JC; Riela AR
    Neurology; 1992 Jun; 42(6):1147-53. PubMed ID: 1603340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation.
    Maas B; Garnett WR; Pellock JM; Comstock TJ
    Ther Drug Monit; 1987; 9(1):28-33. PubMed ID: 3576660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and central side effects of different carbamazepine tablets.
    Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):226-32. PubMed ID: 3997307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results.
    Ruiz ME; Conforti P; Fagiolino P; Volonté MG
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):476-85. PubMed ID: 20878879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and dissolution of proprietary and generic formulations of phenytoin.
    Soryal I; Richens A
    J Neurol Neurosurg Psychiatry; 1992 Aug; 55(8):688-91. PubMed ID: 1527539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.
    Eeg-Olofsson O; Nilsson HL; Tonnby B; Arvidsson J; Grahn PA; Gylje H; Larsson C; Norén L
    J Child Neurol; 1990 Apr; 5(2):159-65. PubMed ID: 2111837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bioinequivalence of carbamazepine tablets with a history of clinical failures.
    Meyer MC; Straughn AB; Jarvi EJ; Wood GC; Pelsor FR; Shah VP
    Pharm Res; 1992 Dec; 9(12):1612-6. PubMed ID: 1488405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of steady-state blood levels of two carbamazepine formulations.
    Jumao-as A; Bella I; Craig B; Lowe J; Dasheiff RM
    Epilepsia; 1989; 30(1):67-70. PubMed ID: 2912719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bioavailability of carbamazepine from two slow-release preparations.
    Reunanen M; Heinonen EH; Nyman L; Anttila M
    Epilepsy Res; 1992 Mar; 11(1):61-6. PubMed ID: 1563339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.